U.S. DNA manufacturing Market Size, Share, Trends, Industry Analysis Report By Type (Plasmid DNA, Synthetic DNA), By Grade, By Application, By End Use

Description

List of Tables

The us dna manufacturing market size is expected to reach USD 11.72 billion by 2034, according to a new study by Polaris Market Research. The report "U.S. DNA Manufacturing Market Size, Share, Trends, Industry Analysis Report By Type (Plasmid DNA, Synthetic DNA), By Grade, By Application, By End Use - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

DNA manufacturing involves the synthetic production of deoxyribonucleic acid (DNA) sequences for use in biotechnology, medicine, and various research applications. Companies synthesize custom DNA strands through chemical processes, enabling advancements in gene therapy, vaccine development, and synthetic biology. DNA manufacturing allows scientists to design and produce genetic molecules for applications such as CRISPR-based gene editing and diagnostic tools. The growing demand for personalized medicine and biopharmaceuticals is driving the expansion of DNA manufacturing, with innovations reducing costs and improving precision. However, ethical concerns, regulatory hurdles, and the complexity of large-scale production pose challenges to the U.S. DNA manufacturing market growth.

The U.S. DNA manufacturing market is growing due to increasing healthcare demands, an aging population, and the rise of chronic diseases. Advances in biotechnology, such as mRNA vaccines and therapeutics, are pushing innovation in the market, while government incentives and private investments are driving market growth. The shift toward personalized medicine and orphan drugs is creating lucrative opportunities for manufacturers.

U.S. DNA Manufacturing Market Report Highlights

In terms of type, the plasmid DNA segment accounted for a major market share in 2024. Pharmaceutical and biotechnology companies drove strong demand for plasmid DNA due to its critical role in cell and gene therapies, DNA vaccines, and viral vector production.

Based on grade, the GMP grade segment held the largest market share in 2024 due to increasing demand for high-quality synthetic DNA in therapeutic applications, including mRNA vaccines, gene therapies, and cell-based treatments.

In terms of application, the cell & gene therapy segment dominated the market share in 2024 due to increasing advancements in CRISPR-based gene editing, CAR-T cell therapies, and viral vector production.

Based on end use, the contract research organizations segment is projected to grow at a robust pace in the coming years, owing to the growing trend of outsourcing in drug discovery and clinical trials.

A few key market players include AGC Biologics, Bionova Scientific, Catalent, Charles River Laboratories, Danaher, Eurofins Genomics, GenScript, Lonza, Thermo Fisher Scientific, Twist Bioscience, and VGXI, Inc.

Polaris Market Research has segmented the U.S. DNA manufacturing market report on the basis of type, grade, application, and end use:

By Type Outlook (Revenue, USD Billion, 2020-2034)

Plasmid DNA

Synthetic DNA

Gene Synthesis

Oligonucleotide Synthesis

By Grade Outlook (Revenue, USD Billion, 2020-2034)

GMP Grade

R&D Grade

By Application Outlook (Revenue, USD Billion, 2020-2034)

Cell & Gene Therapy

Vaccines

Oligonucleotide-based drugs

Others

By End Use Outlook (Revenue, USD Billion, 2020-2034)

Pharmaceutical and Biotechnology Companies

Academic & Research Institutes

Contract Research Organizations

Product Code: PM5838

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. U.S. DNA Manufacturing Market Insights

4.1. U.S. DNA Manufacturing Market - Market Snapshot
4.2. U.S. DNA Manufacturing Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increasing demand for gene therapies
  - 4.2.1.2. Rising demand for personalized medicine
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Strict Regulation Norms
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. U.S. DNA Manufacturing Market Trends
4.6. Value Chain Analysis

5. U.S. DNA Manufacturing Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. U.S. DNA Manufacturing Market, by Type, 2020-2034 (USD Billion)
5.3. Plasmid DNA
- 5.3.1. U.S. DNA Manufacturing Market, by Plasmid DNA, by Region, 2020-2034 (USD Billion)
5.4. Synthetic DNA
- 5.4.1. U.S. DNA Manufacturing Market, by Synthetic DNA, by Region, 2020-2034 (USD Billion)
- 5.4.2. Gene Synthesis
  - 5.4.2.1. U.S. DNA Manufacturing Market, by Gene Synthesis, by Region, 2020-2034 (USD Billion)
- 5.4.3. Oligonucleotide Synthesis
  - 5.4.3.1. U.S. DNA Manufacturing Market, by Oligonucleotide Synthesis, by Region, 2020-2034 (USD Billion)

6. U.S. DNA Manufacturing Market, by Grade

6.1. Key Findings
6.2. Introduction
- 6.2.1. U.S. DNA Manufacturing Market, by Grade, 2020-2034 (USD Billion)
6.3. GMP Grade
- 6.3.1. U.S. DNA Manufacturing Market, by GMP Grade, by Region, 2020-2034 (USD Billion)
6.4. R&D Grade
- 6.4.1. U.S. DNA Manufacturing Market, by R&D Grade, by Region, 2020-2034 (USD Billion)

7. U.S. DNA Manufacturing Market, by Application

7.1. Key Findings
7.2. Introduction
- 7.2.1. U.S. DNA Manufacturing Market, by Application, 2020-2034 (USD Billion)
7.3. Cell & Gene Therapy
- 7.3.1. U.S. DNA Manufacturing Market, by Cell & Gene Therapy, by Region, 2020-2034 (USD Billion)
7.4. Vaccines
- 7.4.1. U.S. DNA Manufacturing Market, by Vaccines, by Region, 2020-2034 (USD Billion)
7.5. Oligonucleotide-based drugs
- 7.5.1. U.S. DNA Manufacturing Market, by Oligonucleotide-based drugs, by Region, 2020-2034 (USD Billion)
7.6. Others
- 7.6.1. U.S. DNA Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)

8. U.S. DNA Manufacturing Market, by End Use

8.1. Key Findings
8.2. Introduction
- 8.2.1. U.S. DNA Manufacturing Market, by End Use, 2020-2034 (USD Billion)
8.3. Pharmaceutical and Biotechnology Companies
- 8.3.1. U.S. DNA Manufacturing Market, by Pharmaceutical and Biotechnology Companies, by Region, 2020-2034 (USD Billion)
8.4. Academic & Research Institutes
- 8.4.1. U.S. DNA Manufacturing Market, by Academic & Research Institutes, by Region, 2020-2034 (USD Billion)
8.5. Contract Research Organizations
- 8.5.1. U.S. DNA Manufacturing Market, by Contract Research Organizations, by Region, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. AGC Biologics
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Bionova Scientific
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Catalent
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Charles River Laboratories
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Danaher
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Eurofins Genomics
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. GenScript
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Lonza
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Thermo Fisher Scientific
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. Twist Bioscience
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
10.11. VGXI, Inc.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Product Benchmarking
- 10.11.4. Recent Development